Conversations powered by KPMG Luxembourg

Where pharma and funds converge | Part 2

23 min · 28 de feb de 2025
Portada del episodio Where pharma and funds converge | Part 2

Descripción

In Part 2 of our podcast episodes on the pharmaceutical and funds industries, Annick Breton (Partner, Head of Consulting, KPMG Luxembourg) and our esteemed guests explore the critical roles that Artificial Intelligence and regulatory decision-makers have in creating a more transparent, trustworthy ecosystem for the two sectors. The key industry players who sat down with Annick were Romain Labbé (Secretary General at the IML), Natasha Deloge (Head of the Innovation Division at the CSSF), Pierre Mottion (Head of DLT and Strategy/Investment Fund Services at Clearstream), and Matthias Van den Eede (Head of Digital Business Development & Beewise at Azimut Investments).

Comentarios

0

Sé la primera persona en comentar

¡Regístrate ahora y únete a la comunidad de Conversations powered by KPMG Luxembourg!

Prueba gratis

Empieza 7 días de prueba

$99 / mes después de la prueba. · Cancela cuando quieras.

  • Podcasts solo en Podimo
  • 20 horas de audiolibros al mes
  • Podcast gratuitos

Todos los episodios

10 episodios

episode Where pharma and funds converge | Part 1 artwork

Where pharma and funds converge | Part 1

In Part 1 of this two-episode special of Conversations powered by KPMG Luxembourg, we dive into the converging worlds of the funds industry and pharmaceuticals. Featuring Annick Breton (Partner, Head of Consulting at KPMG Luxembourg), this episode brings together Romain Labbé (Secretary General at the IML), Natasha Deloge (Head of the Innovation Division at the CSSF), Pierre Mottion (Head of DLT and Strategy/Investment Fund Services at Clearstream), and Matthias Van den Eede (Head of Digital Business Development & Beewise at Azimut Investments), as they discuss the common similarities and challenges affecting their industries. Part 1 of this topic delves into the issues surrounding ongoing consumer confidence and how it is affecting the pharmaceutical and investment funds ecosystems.

28 de feb de 202526 min